NanoViricides

A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Sponsored
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Sponsored
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Sponsored
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Sponsored
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Sponsored
Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
Sponsored
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Sponsored

NanoViricides Recent News

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here.
Sponsored
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here.
Sponsored
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating viral infections.
Sponsored
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many times more deadly than influenza.
Sponsored
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and development related to the COVID virus remains highly relevant and necessary.
Sponsored
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic
Read the latest report on NanoViricides, Inc (NYSE: NNVC) here.
Sponsored
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
New York City is investigating the cause of death for two people who died after contracting monkeypox.
Sponsored
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease.  Since the first reports of monkeypox infection in the United States started popping up in May, cases have now been reported in all 50 states for a total of over 23,000 new infections.
Sponsored
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy
Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No.
Sponsored
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy
Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No.
Sponsored
Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution
More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and unusual outbreak could lead to monkeypox becoming endemic in these large numbers of new countries where it was only seen sporadically before. 
Sponsored
NanoViricides Initiates New Drug Development To Combat Monkeypox Virus
NanoViricides, Inc. (NYSE American: NNVC) reports that it has begun drug development to combat the monkeypox virus.
Sponsored
Omicron BA.4/5 Subvariants Are More Contagious And More Treatment-Resistant, But This Biopharma Reports Working On A Potential Breakthrough
Over the two years since COVID-19 first appeared, people everywhere are becoming less vigilant perhaps simply because they are exhausted. Governments also are easing up on social distancing and mask mandates as they try to regain a sense of normalcy and stability.
Sponsored
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
NanoViricides Begins Drug Development Against Severe Pediatric Hepatitis; Expects To Be Successful In Short Period If Existing Candidates In Drug Library Prove Effective
Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
NanoViricides Reports That It Has Begun Drug Development To Combat Recent Cases Of Severe Pediatric Hepatitis
SHELTON, CONNECTICUT – May 16, 2022 -- NanoViricides, Inc.
Sponsored
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
Photo Credit: Photo by CDC & Klara Kulikova  This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
NanoViricides Says Data Shows Its New Antiviral Could Fight all COVID-19 Variants
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved